Rheumatoid Arthritis (RA) Market, [By Drug Type (Remicade, Remsima, Humira, Enbrel, Rituxan, Reditux, AcellBia, Simponi, Cimzia, Xeljanz, Actemra, Kineret); By Sales Channel (Prescription, Over-the-counter)]; and Geography - Trend, Analysis and Forecast till 2025

Report Summary

由于其全球流行率升高，以及寻找用于治疗类风湿性关节炎（RA）的有效组合药物的持续研发，预计全球类风湿性关节炎（RA）市场预计会增长。

Rheumatoid Arthritis is an autoimmune disorder or a chronic inflammatory disorder that affects individual’s joints. In some cases, this disorder can damage the skin, eyes, blood vessels, lungs, and heart. Usually, RA damages both side of the body i.e. if one side arm or leg is affected with RA than there are chances for other side to be affected too. Rheumatoid arthritis is caused when the immune system attacks the body tissues known as synovium, and affects the lining of the joints. This causes painful swelling that results into bone erosion and joint deformities.

Rheumatoid arthritis not only affects the joints but also has its effect on the non-joint structure of the body that includes; skin, lungs, eyes, kidney, nerve tissue, bone marrow, and blood vessel. Major risk factors that influence rheumatoid arthritis are sex, age, smoking, obesity, genetics, and environmental exposures. On the other hand, RA increases the risk of osteoporosis, dry eyes and mouth, carpal tunnel syndrome, heart problems, and infections.

Rheumatoid arthritis is majorly characterised by symptoms such as, joint pain, joint swelling, loss of joint function, fatigue, fever, weight loss and joint stiffness. Early diagnosis of rheumatoid arthritis helps the doctor in better treatment. However, diagnosis of RA is not that easy it requires several lab test and confirm clinical examination.

Rising awareness about rheumatoid arthritis, and increasing launch of various generic and novel treatments of rheumatoid arthritis are factors to support the growth of global rheumatoid arthritis market.

全球类风湿性关节炎市场主要由因素驱动，例如患有类风湿性关节炎的患者越来越多的患者，以及增加政府的努力，以便在有效地治疗RA。此外，增加了生物制药公司生产的药物和明确定义的监管政策的药物的可接受也将在预测期间涌现类风湿性关节炎市场。此外，增加新型生物药物的发射和通用药物的渗透性也积极影响类风湿性关节炎市场的生长。因此，类风湿性关节炎市场阐明了形式传统治疗方案的转变为组合药物。

Global Rheumatoid Arthritis Market Taxonomy

The global rheumatoid arthritis market is segmented on the basis of drug type, sales channel, and geography.

On the basis of drug type, rheumatoid arthritis market is segmented into:

• 修热
• Remsima
• 鬣狗
• Enbrel
• Rituxan
• Reditux
• AcellBia
• Simponi
• Cimzia
• Xeljanz
• Actemra
• Kineret

On the basis of sales channel type, rheumatoid arthritis market is segmented into:

• 处方
• Over-the-Counter

Geographically, the global rheumatoid arthritis market is categorized into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.需要有效治疗和诊断类风湿性关节炎和复杂的医疗保健基础设施的需要，以引领北美地区的类风湿性关节炎市场。betway体育亚洲版入口

预计北美将在预测期间占据全球类风湿性关节炎市场。推动北美市场增长的主要因素正在增加对各种技术进步的患者意识，并由生物制药公司提高研发支出。此外，各国政府促进发展和开发生物组合药物的研发的倡议将影响全球类风湿性关节炎市场的生长。此外，美国的高质量医疗保健设施，越来越多的患有betway体育亚洲版入口RA的患者将增加这个市场的大量增长。此外，当地政府的强劲报销政策也将在预测期间提高类风湿性关节炎市场。

However, Asia Pacific is expected to grow rapidly during forecast period. Increasing awareness about rheumatoid arthritis, government initiative for promoting the use of combination drugs as an effective treatment, and increased preference for cost-effective generic drugs in the developing countries to govern the global rheumatoid arthritis market during upcoming years.

Key players in the global rheumatoid arthritis market are:

• Pfizer，Inc。
• AbbVie Inc.
• Novartis International AG
• Boehringer Ingelheim GmbH
• Hoffmann-la Roche AG
• Regeneron Pharmaceutical Inc.
• Bristiol-Myers Squibb
• Amgen, Inc.
• Johnson & Johnson Inc.
• Bio Rad Laboratories Inc.
• Thermo Fisher Scientific, Inc.
• Beckman Coulter, Inc.
• Siemens Healthcare GmbH
• Merck and Company
• UCB S.A.